The trademark application RESVIQ was filed by GlaxoSmithKline Biologicals S.A., a corporation established under the laws of the Kingdom of Belgium (the "Applicant"). The application was published for oppositions on November 29, 2021, and it was registered by office on March 8, 2022 without any oppositions.
The application was filed in English (Spanish was selected as the second language).